1.
|
Phase: Phase IV
Type: Health services research, Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CP005, NCT00385983
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Dathyrca 1, EudrCT 2007-002713-39, HB-2007-043, Data register 2007-41-120, NCT00604318
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-2247, NCT00442533
|
|
4.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OXC4T4-302, NCT00507429
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 80
Sponsor: Other
Protocol IDs: CRUK-HILO-BRD/05/83, ISRCTN56078540, EU-20665, CTA-20363/0217/001/0001, EUDRACT-2005-003687-37, NCT00415233
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: Estimabl, CSET 1216, NCT00435851
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-301, NCT00704730
|
|
8.
|
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: UAlexandria, NCT00794053
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2008-09-048, NCT00795782
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CTCT 06-11, NCT00493883
|
|
11.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 5 to 18
Sponsor: NCI
Protocol IDs: NCI-07-C-0189, 07-C-0189, NCT00514046
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CS7017-A-U103, NCT00603941
|
|
13.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-09-C-0047, 09-C-0047, NCI-P08404, NCT00809978
|
|
14.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-09-C-0089, 09-C-0089, NCI-P08387, 8276, NCT00863720
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-04-C-0273, NCI-6332, DELCATH-G990039, NCT00096083
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MDA-2004-0059, 6132, NCI-6132, NCT00104871
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC0476, 6482, NCI-6482, NCT00118248, JHOC-JS0652, JHOC-B/06/174
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CASE-5304, CASE 5304, 7037, NCI-7037, NCT00126568
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NIDDK
Protocol IDs: 060025, 06-DK-0025, NCT00251316
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 18916, NCT00279721
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-14696A, 14696A, 7735, NCI-7735, NCT00381641
|
|
22.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: OSU-06054, 7609, NCI-7609, NCT00390325
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4061027, NCT00389441
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: BRD 03/2-U, NCT00467506
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CO07203, NIH R21CA117117-01A2, NCT00501540
|
